Creative Planning’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.54M | Buy |
55,712
+13,516
| +32% | +$976K | ﹤0.01% | 1485 |
|
|
2026
Q1 | $2.87M | Buy |
42,196
+4,430
| +12% | +$314K | ﹤0.01% | 1606 |
|
|
2025
Q4 | $2.87M | Buy |
37,766
+6,842
| +22% | +$497K | ﹤0.01% | 1410 |
|
|
2025
Q3 | $1.9M | Buy |
30,924
+6,107
| +25% | +$318K | ﹤0.01% | 1593 |
|
|
2025
Q2 | $1.21M | Sell |
24,817
-2,152
| -8% | -$102K | ﹤0.01% | 1704 |
|
|
2025
Q1 | $1.37M | Buy |
26,969
+7,953
| +42% | +$397K | ﹤0.01% | 1464 |
|
|
2024
Q4 | $858K | Buy |
19,016
+8,072
| +74% | +$345K | ﹤0.01% | 1755 |
|
|
2024
Q3 | $406K | Buy |
10,944
+816
| +8% | +$27.3K | ﹤0.01% | 2284 |
|
|
2024
Q2 | $310K | Buy |
10,128
+1,619
| +19% | +$52.4K | ﹤0.01% | 2317 |
|
|
2024
Q1 | $248K | Buy |
+8,509
| New | +$238K | ﹤0.01% | 2410 |
|
|
2022
Q2 | – | Sell |
-7,368
| Closed | -$275K | – | 2477 |
|
|
2022
Q1 | $275K | Hold |
7,368
| – | – | ﹤0.01% | 1688 |
|
|
2021
Q4 | $293K | Sell |
7,368
-27
| -0.4% | -$1.03K | ﹤0.01% | 1636 |
|
|
2021
Q3 | $275K | Buy |
+7,395
| New | +$304K | ﹤0.01% | 1647 |
|
|
2021
Q2 | – | Sell |
-5,105
| Closed | -$242K | – | 2471 |
|
|
2021
Q1 | $242K | Sell |
5,105
-100
| -2% | -$5.94K | ﹤0.01% | 1946 |
|
|
2020
Q4 | $318K | Sell |
5,205
-7,368
| -59% | -$434K | ﹤0.01% | 1592 |
|
|
2020
Q3 | $588K | Hold |
12,573
| – | – | ﹤0.01% | 1051 |
|
|
2020
Q2 | $638K | Buy |
12,573
+1,000
| +9% | +$49.1K | ﹤0.01% | 923 |
|
|
2020
Q1 | $516K | Buy |
11,573
+7,368
| +175% | +$371K | ﹤0.01% | 927 |
|
|
2019
Q4 | $202K | Buy |
+4,205
| New | +$179K | ﹤0.01% | 1632 |
|
|
2018
Q1 | – | Sell |
-14,021
| Closed | -$234K | – | 2103 |
|
|
2017
Q4 | $234K | Buy |
+14,021
| New | +$237K | ﹤0.01% | 1503 |
|
|
2017
Q3 | – | Sell |
-9,071
| Closed | -$166K | – | 3261 |
|
|
2017
Q2 | $166K | Sell |
9,071
-65
| -0.7% | -$876 | ﹤0.01% | 1632 |
|
|
2017
Q1 | $90K | Buy |
9,136
+2,900
| +47% | +$35.1K | ﹤0.01% | 2025 |
|
|
2016
Q4 | $68K | Buy |
6,236
+4,386
| +237% | +$46K | ﹤0.01% | 2143 |
|
|
2016
Q3 | $26K | Buy |
1,850
+750
| +68% | +$6.1K | ﹤0.01% | 2871 |
|
|
2016
Q2 | $8K | Sell |
1,100
-700
| -39% | -$5.13K | ﹤0.01% | 3394 |
|
|
2016
Q1 | $12K | Buy |
1,800
+1,100
| +157% | +$19.1K | ﹤0.01% | 3117 |
|
|
2015
Q4 | $23K | Hold |
700
| – | – | ﹤0.01% | 2747 |
|
|
2015
Q3 | $19K | Buy |
+700
| New | +$29.9K | ﹤0.01% | 2763 |
|
|
2015
Q2 | – | Sell |
-200
| Closed | -$12K | – | 2528 |
|
|
2015
Q1 | $12K | Buy |
+200
| New | +$12.2K | ﹤0.01% | 3090 |
|
Other funds holding PTCT
RI
JT
Creative Planning's PTCT Position: Q2 2026 in Review
Creative Planning increased its PTC Therapeutics (PTCT) stake by 32% in Q2 2026, buying an estimated $976K and bringing the position to 55,712 shares worth $4.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1485.
Creative Planning first reported a position in PTCT in Q1 2015 and has held it in 29 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Creative Planning held 55,712 shares of PTC Therapeutics worth $4.54M as of Q2 2026.
- Creative Planning bought 13,516 PTC Therapeutics shares in Q2 2026, an estimated $976K.
- PTC Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #1485 holding.
- Creative Planning first reported a position in PTC Therapeutics in Q1 2015 and has held it in 29 quarters since.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.